FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 6.8% in September

FibroGen, Inc. (NASDAQ:FGEN) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 4,770,000 shares, a decrease of 6.8% from the August 31st total of 5,120,000 shares. Based on an average trading volume of 2,180,000 shares, the days-to-cover ratio is presently 2.2 days.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FGEN. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd. StockNews.com started coverage on FibroGen in a research note on Friday. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On FibroGen

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alpine Global Management LLC acquired a new position in FibroGen in the first quarter valued at approximately $25,000. Delap Wealth Advisory LLC acquired a new position in shares of FibroGen during the 1st quarter valued at $27,000. Acadian Asset Management LLC boosted its stake in FibroGen by 1.4% during the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after acquiring an additional 34,937 shares in the last quarter. Sei Investments Co. grew its holdings in FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 41,442 shares during the period. Finally, Accel Wealth Management bought a new stake in FibroGen in the first quarter valued at $103,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Stock Down 1.9 %

NASDAQ FGEN traded down $0.01 on Tuesday, hitting $0.39. The company’s stock had a trading volume of 407,461 shares, compared to its average volume of 2,361,300. The company’s 50-day moving average is $0.50 and its 200 day moving average is $1.03. The firm has a market cap of $38.99 million, a PE ratio of -0.16 and a beta of 0.69. FibroGen has a 1-year low of $0.33 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The company had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter last year, the firm posted ($0.65) EPS. On average, equities analysts expect that FibroGen will post -0.91 EPS for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.